Davis Todd C 4
4 · LIGAND PHARMACEUTICALS INC · Filed Jul 2, 2025
Insider Transaction Report
Form 4
Davis Todd C
DirectorChief Executive Officer
Transactions
- Other
Common Stock
2025-06-30$91.08/sh+233$21,221→ 161,467 total
Footnotes (1)
- [F1]These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).